article thumbnail

What Pharmaceutical Manufacturers Value Most from a Hub

Drug Channels

Based on CareMetx research, he outlines the key factors that drug manufacturers value in their hub partners. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. Learn more by downloading CareMetx’s full report: The Evolving Landscape of Digital Healthcare Hubs. Read on for Nasir’s insights. d/b/a Drug Channels Institute.

article thumbnail

Smaller Pharmacies, Bigger Impact: Inside Manufacturers’ Specialty Networks in 2025

Drug Channels

Pharmacies and Pharmacy Benefit Managers , we explore how pharmaceutical manufacturers structure their specialty pharmacy networksand how smaller, independent pharmacies have emerged as dominant players in exclusive networks. Read more 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Moving Beyond Mitigation: Cracking the Maximizer Code to Protect Patient Affordability

Drug Channels

Logan explores how maximizers have reshaped the patient affordability landscape and pressured pharmaceutical manufacturers to adapt their copay strategies. Read more » © 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Read on for Logan’s insights. All rights reserved.

article thumbnail

New SingleCare Pharma Solutions Help Drugmakers Reach Cash-Paying Patients

Drug Channels

Today’s guest post comes from Josh Bliss, SVP of Customer Acquisition and Head of Pharma Solutions at SingleCare Josh discusses the challenges that pharmaceutical manufacturers face connecting with consumers who could benefit from patient financial support programs. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc.

article thumbnail

Gross-to-Net Bubble Update: 2021 Pricing Realities at 10 Top Drugmakers

Drug Channels

Time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. This year’s review includes 10 companies: Eli Lilly and Company, Genentech, GlaxoSmithKline, Janssen, Merck, Novartis, Novo Nordisk, Sanofi, Takeda, and UCB.

article thumbnail

Five (or Maybe Six?) Reasons that the Largest PBMs Operate Group Purchasing Organizations

Drug Channels

In recent years, each of these companies has launched new group purchasing organizations (GPOs) to further consolidate the number of covered lives in rebate negotiations with pharmaceutical manufacturers. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. to 1:30 p.m. Click here to learn more and register.

article thumbnail

GoodRx: Evolving & Expanding Integrated Platform Partnerships to Drive Access, Affordability & Outcomes

Drug Channels

Rick explains why patients and pharmaceutical manufacturers now pay a greater share of prescription costs. He outlines GoodRx's services that address the twin challenges when the patient is the payer and the manufacturer faces intense gross-to-net pressures. Read on for Rick’s insights. All rights reserved.